该公司产品线中的其他RAS(ON)抑制剂包括RMC-0708(KRAS问61H),目前正在进行IND支持开发,RMC-8839(KRAS)G13C),以及靶向其他RAS变体的其他化合物。临床开发中的RAS伴随抑制剂包括RMC-4630(SHP2)和RMC-5552(mTORC1 / 4EBP1)
today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, covalent, mutant-selective KRASG12D(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12...